ThromboGenics and BioInvent get clearance for trial
The drug, TB-402, is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. The study is a dose escalation
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.